BD Announces CE Marking for Liverty® TIPS Endoprosthesis expanding therapeutic options for patients with advanced liver disease
FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE marking application for the Liverty® TIPS endoprosthesis, bringing innovation to portal hypertension care across the European Union. Designed to expand treatment options for patients with cirrhosis and portal hypertension complications, our next-generation device with adjustable diameter represents BD’s latest advancement in interventional therapies for complex liver diseases. Safety and efficacy data from the pivotal ARCH clinical trial evaluating the Liverty® TIPS endoprosthesis will be presented for the first time at the Society of Interventional Radiology (SIR) annual scientific meeting on April 12, 2026.
Cirrhosis is a significant global health issue, with an estimated 58 million people worldwide living with this disease, as per the latest Global Burden of Disease study. Cirrhosis can lead to portal hypertension, a serious condition that can result in potentially life-threatening complications such as variceal bleeding and fluid buildup in the abdomen or chest. Portosystemic intrajugular transhepatic shunt (TIPS) procedures help alleviate symptoms caused by elevated portal pressure by reducing this pressure and improving blood flow.
The Liverty® TIPS endoprosthesis is designed to support individualized patient management, offering an adjustable inner diameter of 6 to 10 mm and the broadest range of currently available covered TIPS endoprosthesis lengths. Key features include a flexible, self-expanding nitinol frame and a double-layer ePTFE lining impregnated with carbon on the inner surface. The device is fully anchored using a triaxial delivery system designed to ensure accurate placement, good control, and ease of use.
“For patients with portal hypertension-related complications, it is essential to have safe, effective, and adaptable therapeutic options,” said Rima Alameddine, International President of Peripheral Intervention at BD. “With CE marking of the Liverty® TIPS endoprosthesis, we are introducing an innovative, adjustable solution that helps physicians tailor therapy and enhance long-term outcomes potential.”
BD also announced that results from the ARCH clinical study, an international, prospective, multicenter, single-arm clinical study evaluating the safety and efficacy of the Liverty® TIPS endoprosthesis in treating portal hypertension-related complications, will be presented for the first time at a conference by the international principal investigator, Professor Ziv Haskal, MD, during the SIR congress in April.
“The Liverty® TIPS endoprosthesis represents a significant advancement in how we care for patients with severe portal hypertension complications,” said Dr. Haskal. “Its adjustable diameter and design enable physicians to better tailor the shunt to the patient’s unique physiology, which is a key factor for creating safe and effective TIPS. This trial provides the first and only prospective data describing outcomes with small-diameter calibrated TIPS in treating all major portal hypertension complications. I look forward to presenting the ARCH study results at the SIR congress.”
In the United States, the Liverty® TIPS endoprosthesis is an investigational device limited by US law to investigational use only.
About BD BD is one of the world’s largest medical technology companies dedicated to advancing the world of health by driving innovation in essential medical devices, connected care, biopharmaceutical systems, and interventional technologies. The company supports frontline healthcare professionals by developing transformative technologies, solutions, and services that optimize clinical operations and improve patient care. With a global presence and over 60,000 employees, BD delivers billions of products annually that have a positive impact on global health. By working closely with its customers, BD can help improve outcomes, reduce costs, increase clinical efficiency, enhance safety, and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn www.linkedin.com/company/bd1/, Twitter @BDandCo, or Instagram @becton_dickinson.
1: Duo H, You J, Du S, Yu M, Wu S, Yue P, et al. Liver cirrhosis in 2021: Global Burden of Disease study. PLOS One. 2025; 20(7): e0328493. doi: 10.1371/journal.pone.032849 2: Carroll A, Boike JR. Tips for TIPS recipients: A guide to patient-centered TIPS. Clin Liver Dis (Hoboken). 2024; 23(1): e0091. doi: 10.1097 / CLD.0000000000000091
Photo – https://mma.prnewswire.com/media/2950341/BD_Delivers_Next_Generation_TIPS_Innovation.jpg Logo – https://mma.prnewswire.com/media/1479210/BD_Logo.jpg
